Knight Therapeutics’ (GUD) “Accumulate” Rating Reaffirmed at Bloom Burton

Share on StockTwits

Bloom Burton reaffirmed their accumulate rating on shares of Knight Therapeutics (TSE:GUD) in a research report report published on Friday morning.

A number of other analysts have also commented on GUD. Raymond James set a C$10.25 target price on shares of Knight Therapeutics and gave the stock an outperform rating in a report on Thursday, July 12th. TD Securities lifted their target price on shares of Knight Therapeutics from C$9.50 to C$10.00 in a report on Friday, August 10th. One equities research analyst has rated the stock with a hold rating and five have given a buy rating to the company. The stock has a consensus rating of Buy and an average target price of C$10.15.

GUD traded up C$0.11 during trading on Friday, reaching C$8.30. 198,100 shares of the company’s stock were exchanged, compared to its average volume of 134,380. Knight Therapeutics has a fifty-two week low of C$7.38 and a fifty-two week high of C$8.81.

Knight Therapeutics (TSE:GUD) last released its earnings results on Thursday, November 8th. The company reported C$0.03 EPS for the quarter, hitting analysts’ consensus estimates of C$0.03. The business had revenue of C$3.22 million for the quarter, compared to analyst estimates of C$2.26 million. Equities analysts expect that Knight Therapeutics will post 0.130000001435583 EPS for the current year.

Knight Therapeutics Company Profile

Knight Therapeutics Inc operates as a specialty pharmaceutical company in Canada and internationally. The company is involved in developing, acquiring, in-licensing, out-licensing, marketing, and distributing pharmaceutical products, consumer health products, and medical devices. Its commercialized products include Movantik to treat opioid induced constipation; Impavido, an alkyllysophospholipid analogue drug for visceral and cutaneous Leishmaniasis; Neuragen to treat pain associated with diabetic and peripheral neuropathy; Synergy family consumer health products; and Flat Tummy Tea, a herbal detox tea.

Further Reading: The Discount Rate – What You Need to Know

Analyst Recommendations for Knight Therapeutics (TSE:GUD)

Receive News & Ratings for Knight Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Knight Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Ameriprise Financial, Inc.  Stake Lifted by Sumitomo Mitsui Trust Holdings Inc.
Ameriprise Financial, Inc. Stake Lifted by Sumitomo Mitsui Trust Holdings Inc.
Toronto Dominion Bank Reduces Stake in Oracle Co.
Toronto Dominion Bank Reduces Stake in Oracle Co.
Analyzing China Ceramics  and OLYMPUS Corp/S
Analyzing China Ceramics and OLYMPUS Corp/S
SG Americas Securities LLC Has $6 Million Position in Fifth Third Bancorp
SG Americas Securities LLC Has $6 Million Position in Fifth Third Bancorp
Jacobs Engineering Group Inc  Stake Increased by SG Americas Securities LLC
Jacobs Engineering Group Inc Stake Increased by SG Americas Securities LLC
SG Americas Securities LLC Purchases 132,788 Shares of General Mills, Inc.
SG Americas Securities LLC Purchases 132,788 Shares of General Mills, Inc.


Leave a Reply

© 2006-2018 Ticker Report